Testosterone, Stroke Risk, and the Types of Polycythemia: And the Question of Inject once vs twice a week

Secondary vs. Primary Polycythemia: Stroke Risk Differences

Secondary polycythemia generally poses a lower risk of cerebrovascular accidents (CVAs) compared to primary polycythemia (polycythemia vera, PV) due to differences in underlying mechanisms, associated comorbidities, and treatment responsiveness.

Key Differences in CVA Risk

Factor	Secondary Polycythemia	Primary Polycythemia (PV)
Primary Cause	External triggers (e.g., hypoxia, tumors, smoking)	Intrinsic bone marrow mutation (e.g., JAK2 V617F)
Thrombotic Mechanisms	Elevated hematocrit ↑ blood viscosity	Elevated hematocrit + platelet dysfunction + chronic inflammation
Comorbidities	Often reversible (e.g., sleep apnea, COPD)	Chronic hypertension, dyslipidemia, leukocytosis
Platelet Activity	Typically normal	Overactive platelets ↑ adhesion/aggregation
Treatment Impact	Resolves with correction of underlying cause	Requires lifelong management (e.g., phlebotomy, cytoreduction)

Why Secondary Polycythemia Is Lower Risk

Reversibility:
- Secondary polycythemia often resolves with treatment of the root cause (e.g., oxygen therapy for COPD, nephrectomy for EPO-secreting tumors).
- PV is a chronic, progressive disorder with no cure.
Platelet Dysfunction:
- PV involves clonal platelet abnormalities (e.g., hyperactivation) and leukocytosis, which amplify thrombotic risk.
- Secondary polycythemia lacks these intrinsic platelet defects.
Inflammation and Cytokines:
- PV produces pro-inflammatory cytokines (e.g., IL-6) and elevated leukocyte counts, promoting endothelial damage and clotting.
- Secondary polycythemia lacks this chronic inflammatory state.
Cardiovascular Risk Factors:
- PV patients frequently have hypertension, obesity, and smoking habits, which compound stroke risk.
- Secondary polycythemia’s CVA risk is more tightly linked to hematocrit alone.
Treatment Response:
- Phlebotomy in PV paradoxically increases thrombotic risk in some cases (e.g., iron deficiency → reactive thrombocytosis)
- Reducing hematocrit in secondary polycythemia (e.g., via smoking cessation) directly lowers viscosity and CVA risk

Exceptions in Secondary Polycythemia

Untreated Hypoxia: Chronic hypoxia (e.g., severe sleep apnea) can lead to extreme erythrocytosis, significantly raising CVA risk
EPO-Secreting Tumors: Renal cell carcinoma or hepatic tumors may cause severe, persistent polycythemia requiring aggressive management.

The difference in stroke (CVA) risk between primary and secondary polycythemia is highly significant.

In a clinical study, the incidence of cerebrovascular disease (CVD, including stroke) was 43% in patients with primary polycythemia (polycythemia vera), compared to only 8% in those with secondary polycythemia1. This demonstrates that patients with primary polycythemia are more than five times as likely to experience a stroke or related cerebrovascular event as those with secondary polycythemia.
Primary polycythemia (PV) carries higher risk because it involves not just increased red blood cells, but also abnormal platelet function, chronic inflammation, and genetic mutations (such as JAK2 V617F) that drive both blood thickening and a pro-thrombotic state. These factors make PV patients particularly susceptible to both arterial and venous thrombosis, including recurrent strokes.
Secondary polycythemia, while it can still cause stroke due to increased blood viscosity (especially in extreme or untreated cases), lacks the intrinsic bone marrow and platelet abnormalities of PV. Its risks are more closely tied to the degree of hematocrit elevation and are often reversible if the underlying cause is addressed.

Primary polycythemia is associated with a much higher and more persistent risk of stroke than secondary polycythemia, making the difference clinically and statistically significant

How to Fix Numbers….

Therapeutic phlebotomy is initiated based on specific hematocrit (Hct) and hemoglobin (Hgb) thresholds, which vary depending on the underlying condition:Therapeutic phlebotomy is a simple medical procedure where a small amount of blood is drawn from your body—similar to donating blood. It’s used to reduce the number of red blood cells when they are too high, which can make your blood too thick and increase the risk of problems like blood clots or strokes.

1. Polycythemia Vera (Primary Polycythemia)

Threshold for Initiation:
- Hct ≥45% in both men and women is the standard trigger for phlebotomy to reduce thrombotic risk.
- The CYTO-PV trial demonstrated a 4-fold reduction in cardiovascular events when Hct is maintained <45% compared to higher levels.

2. Secondary Polycythemia

Testosterone-Induced:
- Phlebotomy is considered when Hct ≥54% (Hgb ≥180 g/L) to mitigate vascular risks, though guidelines note this threshold is not always effective for long-term control1 6.
Hypoxia-Driven (e.g., COPD, Sleep Apnea):
- No universal Hct threshold, but phlebotomy may be used if Hct exceeds 50–55% and symptoms (e.g., headaches, dizziness) persist.

3. Hemochromatosis

Phlebotomy is guided by ferritin levels (target: 50–100 µg/L) rather than Hct/Hgb. Iron overload, not erythrocytosis, drives the need for treatment.

Key Guidelines by Condition

Condition	Hct Threshold for Phlebotomy	Key Evidence Source
Polycythemia Vera	Initiate at ≥45%, target <45%	CYTO-PV trial, AAFP
Testosterone-Induced	≥54% (Hgb ≥180 g/L)	Aetna policy
Hypoxia-Related	≥50–55% (symptomatic)	PMC studies

Why Twice A Week Dosing may be More Beneficial

Injecting testosterone twice weekly helps prevent polycythemia (elevated red blood cell count) by stabilizing serum testosterone levels, thereby avoiding the supraphysiological peaks and troughs that drive excessive erythropoiesis. Here’s how it works:

1. Avoids Testosterone “Spikes”

Once-weekly injections of short-acting esters (e.g., testosterone cypionate) cause large fluctuations:
- Peaks: Supraphysiological testosterone levels shortly after injection overstimulate erythropoietin (EPO) production and bone marrow activity.
- Troughs: Rapidly declining levels trigger reactive mechanisms (e.g., rebound EPO release) that further stimulate red blood cell (RBC) production.
Twice-weekly injections smooth these fluctuations, maintaining levels within a narrower, more physiological range.

2. Reduces Erythropoietic Stimuli

EPO Regulation: Testosterone spikes transiently increase EPO, which drives RBC production. Stable levels minimize this effect.
Hepcidin Suppression: High testosterone levels suppress hepcidin, increasing iron availability for erythropoiesis. Stable levels reduce iron overload risk.
Bone Marrow Overdrive: Peaks cause excessive RBC production, while troughs fail to suppress compensatory mechanisms.

3. Pharmacokinetic Advantages

Studies show short-acting injectables (e.g., testosterone cypionate) cause erythrocytosis in 66.7% of users with once-weekly dosing vs. 7% with extended-release formulations or more frequent dosing. Transdermal gels/oral agents (stable levels) have far lower erythrocytosis rates (<13%)
Half-Life: Testosterone cypionate has an ~8-day half-life. Twice-weekly dosing maintainssteady-state levels, avoiding the “rollercoaster” effect. Dose-Dependent Risk: Polycythemia risk correlates with peak testosterone levels. Splitting doses lowers peak concentrations while sustaining therapeutic effects.

4. Clinical Evidence

Studies show short-acting injectables (e.g., testosterone cypionate) cause erythrocytosis in 66.7% of users with once-weekly dosing vs. 7% with extended-release formulations or more frequent dosing.
Transdermal gels/oral agents (stable levels) have far lower erythrocytosis rates (<13%).

Practical Example

Twice-weekly: 100 mg every 3.5 days → peaks at 800 ng/dL, troughs at 500 ng/dL → reduced stimulation.
Once-weekly: 200 mg testosterone cypionate → peaks at 1,200 ng/dL, troughs at 300 ng/dL → high erythropoietic drive.

Factor	Once-Weekly Injections	Twice-Weekly Injections
Testosterone Peaks	Supraphysiological (↑ EPO/hepcidin suppression)	Near-physiological (↓ stimulation)
Erythropoiesis	Overstimulated	Moderately regulated
Hematocrit Risk	High (up to 66.7%)	Lower (~10–20%)

Summary

Secondary polycythemia carries a lower CVA risk than PV because its thrombotic drivers are primarily reversible (e.g., hypoxia) and lack the chronic inflammation, platelet dysfunction, and comorbidities seen in PV. However, untreated secondary cases with extreme hematocrit elevation or comorbidities (e.g., smoking) can still pose significant stroke risk. Twice-weekly injections stabilize testosterone levels, reducing the hormonal surges that drive excessive RBC production. This approach is particularly critical for patients using short-acting esters and those with baseline risk factors (e.g., sleep apnea, obesity).

At Nervana Medical in Sandy, Utah, we take a proactive and evidence-based approach to managing potential side effects of BHRT/ Bioidentical Hormone Replacement therapy/testosterone therapy, including elevated red blood cell counts (secondary polycythemia). Therapeutic phlebotomy, a simple and effective procedure similar to donating blood, helps reduce hematocrit levels and blood viscosity, lowering the risk of cardiovascular events without compromising the benefits of testosterone optimization. If you’re on TRT and have concerns about blood thickness or stroke risk, our experienced providers are here to guide you with safe, individualized care.

Schedule a consultation today to ensure your hormone therapy is as effective and safe as possible.

Book Now